Humacyte

Humacyte is proud to announce that the FDA has granted full approval for our Acellular Tissue Engineered Vessel, a first-in-class, universally implantable, bioengineered human vessel for extremity arterial trauma. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries. Congratulations to our incredible team and partners who made this possible! Read our Press Release Here: https://xmrrwallet.com/cmx.plnkd.in/ehm-q6CX See the Prescribing Information, including Boxed Warning: https://xmrrwallet.com/cmx.pbit.ly/4dl5tuL #Humacyte #FDAApproval #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA

The 2025 Military Health System Research Symposium (#MHSRS) kicks off today! We’re joining military medical researchers, innovators, and leaders from across the globe to share breakthroughs that advance the health and readiness of our warfighters. Stay tuned for updates on the future of military medicine—from battlefield trauma care to cutting-edge brain health research. #MilitaryHealth #WarfighterCare

What a strong beginning to MHSRS 2025! Join us on Monday, August 4th for a session on ATEV™ at MHSRS. 🕔 Don’t miss Charles Fox, MD, LTC (Ret.), U.S. Army, presenting: “Real-World Implementation of a Bioengineered Vascular Conduit in Wartime Medicine: Lessons from Ukraine” 📅 Time: 1700 – 1715 (5:00–5:15 PM) EST 📍 Session ID: MHSRS-25-16832 This is the final talk in a 2-hour session running from 3:30–5:30 PM, followed by a 15-minute Q&A. About Dr. Fox: Director of Vascular Surgery, University of Maryland Capital Region Attending Surgeon at Shock Trauma & University of Maryland Medical Centers Associate Professor of Surgery, University of Maryland School of Medicine U.S. Army: LTC (Ret.), Combat Medic at 82nd Airborne Division Learn more about Humacyte’s Acellular Tissue Engineered Vessel (ATEV™) and ECAT approval visit us at Booth 1021 to connect with our clinical and sales teams. https://xmrrwallet.com/cmx.phumacyte.com Trademarks are property of Humacyte Global, Inc © 2025 Humacyte Global Inc. All Rights Reserved.   #Humacyte #Innovation #Biotech #MHSRS2025 #MHSRS #MTEC #MilitaryMedicine #ECATapproved #DefenseHealth $HUMA

Stop by booth 1021 during the MHSRS conference from August 4th – 7th. With our recent ECAT (Electronic Catalog) listing you can find our product in the DLA (Defense Logistics Agency) medical supply chain procurement system. The Humacyte team is ready to let you handle and help you learn more about our FDA Approved Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. Our sales and medical affairs teams will be there to answer all your questions. Learn more about Symvess here: https://xmrrwallet.com/cmx.plnkd.in/e2jnB-eg SEE FULL PRESCRIBING INFORMATION INCLUDING BOXED WARNING AND IMPORTANT SAFETY INFORMATION at https://xmrrwallet.com/cmx.pbit.ly/4dl5tuL   INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. Trademarks are property of Humacyte Global, Inc © 2025 Humacyte Global Inc. All Rights Reserved. US-SYM-000262 @affirmative-solutions Apiary Medical Inc. #Humacyte #Innovation #Biotech #MHSRS2025 #MHSRS #MTEC #MilitaryMedicine #ECATapproved #DefenseHealth $HUMA

Exciting news coming from MTEC member, Humacyte! Congratulations!! Learn more about MTEC projects that Humacyte has worked on in their member profile: https://xmrrwallet.com/cmx.plnkd.in/gX4usnR5 #MTECmember #medtech #innovation #FDAapproved FDA

Major Milestone in Biotech Options for the U.S. Military Humacyte has officially made its first sale of Symvess™, a bioengineered human vessel, to a U.S. Military Treatment Facility—marking a breakthrough in patient care for service members and veterans. Following FDA approval and ECAT listing, Symvess is now available across 35 military hospitals and 160 VA facilities. This is more than a sale - it's a step toward transforming how we treat vascular trauma. Read the full press release here: https://xmrrwallet.com/cmx.plnkd.in/earTginP Trademarks are property of Humacyte Global, Inc © 2025 Humacyte Global Inc. All Rights Reserved. #Biotech #RegenerativeMedicine #MilitaryHealth #Humacyte #Symvess #FDAApproved #InnovationInCare #VeteransHealth #HealthcareBreakthrough

SAVING LIVES IN UKRAINE- A VASCULAR SURGEON'S STORY Great to speak with Ukrainian Vascular Surgeon, Dr. Oleksandr Sokolov, about his incredible experiences treating severely war-wounded patients in an active combat zone in Ukraine. He described his use of Acellular Tissue Engineered Vessels for vascular reconstruction following combat trauma and the advantages compared to other modalities, such as autologous vein and PTFE or Gore-Tex. He explains how this technology can improve patient outcomes even in the most austere environments. Keep an eye out for an updated series from his team in Military Medicine, the AMSUS - The Society of Federal Health Professionals journal. We are also looking forward to putting out this video and podcast episode on WarDocs soon. Excelsior Surgical Society American College of Surgeons Society for Vascular Surgery European Society for Vascular Surgery Humacyte Joint Trauma System (JTS) DoD Center of Excellence for Trauma Oxford University Press

Humacyte has just announced that Symvess™ has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency, which makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilities. For more details, please read the full press release here: https://xmrrwallet.com/cmx.plnkd.in/eQK3PVJY #Humacyte #HealthcareInnovation #Bioengineering #Biotech

In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. https://xmrrwallet.com/cmx.plnkd.in/eZ3BK_Kq #dialysis